2'-cyano-2'-deoxyarabinofuranosylcytosine has been researched along with cyc 682 in 4 studies
| Studies (2'-cyano-2'-deoxyarabinofuranosylcytosine) | Trials (2'-cyano-2'-deoxyarabinofuranosylcytosine) | Recent Studies (post-2010) (2'-cyano-2'-deoxyarabinofuranosylcytosine) | Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) |
|---|---|---|---|---|---|
| 31 | 0 | 6 | 30 | 5 | 18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanaoka, K; Hisaoka, M; Ikeda, T; Iwabuchi, H; Kaneko, M; Kobayashi, T; Kurakata, S; Matsuda, A; Mitsuhashi, Y; Miura, S; Nakagawa, A; Nomura, T; Sasaki, T; Shibayama, T; Suzuki, M; Tanaka, K; Tanzawa, F; Tomida, A; Tsuruo, T; Wataya, Y | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Liu, XJ; Nowak, B; Plunkett, W; Wang, YQ | 1 |
| Al Abo, M; Huang, SY; Kiselev, E; Liu, X; Plunkett, W; Pommier, Y; Rajapakse, VN; Sasanuma, H; Takeda, S | 1 |
4 other study(ies) available for 2'-cyano-2'-deoxyarabinofuranosylcytosine and cyc 682
| Article | Year |
|---|---|
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biotransformation; Breast Neoplasms; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Deoxycytidine Kinase; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; KB Cells; Leukemia P388; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Mitomycin; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Rats; Rats, Nude; Specific Pathogen-Free Organisms; Stomach Neoplasms; Tumor Cells, Cultured; Vincristine | 1999 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; CHO Cells; Cricetinae; Cricetulus; Cytarabine; Cytosine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Gemcitabine; Homologous Recombination; Inhibitory Concentration 50; Prodrugs | 2012 |
TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
Topics: Arabinonucleosides; BRCA2 Protein; Camptothecin; Colorectal Neoplasms; Cytarabine; Cytosine; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; DNA Replication; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Phosphoric Diester Hydrolases; Poly (ADP-Ribose) Polymerase-1 | 2017 |